Hong Zhao
ORCID: 0000-0002-5515-6139Also affiliated with Lanzhou University of Technology, Lanzhou University
Pilot corpus only
This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.
Indexed papers
Why this DataRank?
An author's DataRank is the sum of the DataRanks of all 5 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.
Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.
Read the full methodology →Papers
Driven by 8 papers. Top paper: “FDA Approval Summary: Nivolumab in Combination with Ipilimumab for the Treatment of Unresectable Malignant Pleural Mesothelioma”.
Paz J. Vellanki, Erin Larkins, Somak Chatterjee, Pallavi S. Mishra-Kalyani, Youwei Bi +11 more
Yongchen Xu, Hong Zhao, Hong Sui, Hongyan Liang, Xiaofeng Jiang +1 more
Jason D. Goldman, Hong Zhao, Alec Pankow, Fred Okuku, Michael Schmitt +6 more
Xiang Ju, Hong Zhao, Zhi You, Run Han, Zhen Luo +1 more
Zi-Qing Yu, Yi-Zhou Zhang, Yi-Qiao Deng, Xiao Chen, Hua-Yuan Liu +3 more
Sha Zhang, Xia Liu, Hong Zhao, Hanxi Li
Yueming Chen, Min Mao, Jun Yang, Jing Chang, Hong Zhao
Hong Zhao, Stephen T.C. Wong, Yunjie He